Eledon Pharmaceuticals, Inc. (ELDN) 10-Year Financial Performance & Capital Metrics

ELDN • • Industrial / General

HealthcareBiotechnologyAutoimmune & Inflammatory DiseasesDermatology & Autoimmune

AboutEledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical trials for the treatment of ALS, and Phase 2 clinical trials in islet cell transplantation for the treatment of type 1 diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.Show more

Revenue $0
EBITDA -$70M -64.7%
Net Income -$36M +69.0%
EPS (Diluted) -0.75 +54.3%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -57.73% +77.4%
ROIC -104.28% +49.1%
Debt/Equity 0.01 -84.8%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓High quality earnings: Operating CF exceeds net income
✓Trading at only 0.9x book value

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Weak momentum: RS Rating 12 (bottom 12%)
✗Shares diluted 97.2% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-3.08%

EPS CAGR

10Y-

5Y-

3Y-

TTM78.91%

ROCE

10Y Avg-56.91%

5Y Avg-34.27%

3Y Avg-45.97%

Latest-56.24%

Peer Comparison

Dermatology & Autoimmune

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
AUPHAurinia Pharmaceuticals Inc.	1.96B	14.87	378.37	33.97%	29.28%	21.28%	2.25%	0.21
ARGXargenx SE	50.33B	813.24	63.63	78.6%	23.34%	15.14%		0.01
INVAInnoviva, Inc.	1.48B	19.76	54.89	15.54%	32.78%	12.61%	12.75%	0.65
GLPGGalapagos N.V.	2.24B	34.03	30.38	14.99%	-151.94%	-15.16%		0.00
PTGXProtagonist Therapeutics, Inc.	5.3B	84.75	20.04	6.24%	21.94%	7.11%	3.45%	0.02
ALMSAlumis Inc. Common Stock	2.84B	24.17	-2.33		-11.08%	-63.71%		0.12
PHATPhathom Pharmaceuticals, Inc.	1.17B	14.98	-2.83	80.01%	-186.53%
ORKAOruka Therapeutics, Inc.	1.57B	32.50	-6.51			-22.44%		0.00

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-	-	-	-
Cost of Goods Sold+	109K	35K	22K	11K	182K	183K	195K	373K	374K	359K
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	-109K	-35K	-22K	-11K	-182K	-183K	-195K	-373K	-374K	-359K
Gross Margin %	-	-	-	-	-	-	-	-	-	-
Gross Profit Growth %	-1878.31%	0.68%	0.37%	0.5%	-15.55%	-0.01%	-0.07%	-0.91%	-0%	0.04%
Operating Expenses+	45.26M	38.12M	13.12M	14.06M	14M	13.1M	36.67M	39.41M	42.63M	70.22M
OpEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Selling, General & Admin	12.62M	13.1M	11.1M	7.24M	5.87M	6.97M	12.94M	12.33M	12.31M	18.25M
SG&A % of Revenue	-	-	-	-	-	-	-	-	-	-
Research & Development	32.64M	25.02M	2.02M	6.82M	8.13M	6.13M	23.73M	27.08M	30.31M	51.96M
R&D % of Revenue	-	-	-	-	-	-	-	-	-	-
Other Operating Expenses	0	0	5K	-5K	0	0	0	0	0	0
Operating Income+	-45.26M	-38.12M	-13.12M	-14.06M	-14.18M	-13.28M	-36.87M	-39.78M	-43M	-70.58M
Operating Margin %	-	-	-	-	-	-	-	-	-	-
Operating Income Growth %	-0.93%	0.16%	0.66%	-0.07%	-0.01%	0.06%	-1.78%	-0.08%	-0.08%	-0.64%
EBITDA+	-45.15M	-38.09M	-13.1M	-14.05M	-14M	-13.1M	-36.67M	-39.41M	-42.63M	-70.22M
EBITDA Margin %	-	-	-	-	-	-	-	-	-	-
EBITDA Growth %	-0.93%	0.16%	0.66%	-0.07%	0%	0.06%	-1.8%	-0.07%	-0.08%	-0.65%
D&A (Non-Cash Add-back)	109K	35K	22K	11K	182K	183K	195K	373K	374K	359K
EBIT	-45.09M	-6.93M	-13.12M	-14.06M	-16.01M	-23.21M	-36.86M	-87.97M	-116.54M	-35.75M
Net Interest Income+	0	0	0	0	0	0	0	0	0	0
Interest Income	0	0	0	0	0	0	0	0	0	0
Interest Expense	174K	0	0	0	0	0	0	0	0	0
Other Income/Expense	174K	-527K	5K	-5K	-1.83M	-9.93M	7K	-48.19M	-73.54M	34.82M
Pretax Income+	-45.09M	-37.96M	-13.12M	-14.06M	-16.01M	-23.21M	-36.86M	-87.97M	-116.54M	-35.75M
Pretax Margin %	-	-	-	-	-	-	-	-	-	-
Income Tax+	0	136K	0	-5K	0	-404K	-2.35M	0	0	431K
Effective Tax Rate %	1%	1%	1%	1%	1%	0.98%	0.94%	1%	1%	1.01%
Net Income+	-45.09M	-37.96M	-13.12M	-14.06M	-16.01M	-22.81M	-34.51M	-87.97M	-116.54M	-36.18M
Net Margin %	-	-	-	-	-	-	-	-	-	-
Net Income Growth %	-0.94%	0.16%	0.65%	-0.07%	-0.14%	-0.42%	-0.51%	-1.55%	-0.32%	0.69%
Net Income (Continuing)	-45.09M	-5.66M	-13.12M	-14.06M	-16.01M	-22.81M	-34.51M	-87.97M	-116.54M	-36.18M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-324.85	-1785.21	-50.47	-28.11	-27.27	-15.72	-2.33	-6.13	-1.64	-0.75
EPS Growth %	0.44%	-4.5%	0.97%	0.44%	0.03%	0.42%	0.85%	-1.63%	0.73%	0.54%
EPS (Basic)	-324.85	-1785.21	-50.47	-28.11	-27.27	-15.72	-2.33	-6.13	-0.00	-0.75
Diluted Shares Outstanding	138.79K	21.26K	259.87K	500.3K	655.52K	1.45M	14.82M	14.29M	24.62M	48.54M
Basic Shares Outstanding	138.79K	21.26K	259.87K	500.3K	655.52K	1.45M	14.82M	14.29M	24.62M	48.54M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	67.17M	29.54M	19M	14.28M	9.97M	115.63M	88.35M	59.52M	56.13M	143.73M
Cash & Short-Term Investments	63.96M	27.4M	17.23M	12.97M	8.79M	114.19M	84.83M	56.41M	51.1M	140.18M
Cash Only	24.02M	23.22M	17.23M	12.97M	8.79M	114.19M	84.83M	56.41M	4.61M	20.55M
Short-Term Investments	39.93M	4.17M	0	0	0	0	0	0	46.49M	119.63M
Accounts Receivable	0	0	0	594K	245K	110K	0	0	0	0
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	881K	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	1.77K	-	-	-	-	-
Other Current Assets	3.21M	47K	88K	36K	54K	38K	34K	28K	90K	729K
Total Non-Current Assets+	804K	218K	1.89M	2.75M	960K	81.56M	82.2M	33.27M	32.94M	33.67M
Property, Plant & Equipment	489K	98K	25K	14K	321K	138K	768K	739K	365K	926K
Fixed Asset Turnover	-	-	-	-	-	-	-	-	-	-
Goodwill	0	0	1.87M	1.87M	0	48.65M	48.65M	0	0	0
Intangible Assets	0	0	0	0	0	32.39M	32.39M	32.39M	32.39M	32.39M
Long-Term Investments	270K	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	45K	120K	0	869K	639K	383K	400K	150K	186K	363K
Total Assets+	67.97M	29.76M	20.89M	17.03M	10.93M	197.19M	170.55M	92.79M	89.07M	177.41M
Asset Turnover	-	-	-	-	-	-	-	-	-	-
Asset Growth %	-0.37%	-0.56%	-0.3%	-0.19%	-0.36%	17.04%	-0.14%	-0.46%	-0.04%	0.99%
Total Current Liabilities+	6.16M	2.82M	1.44M	2.53M	1.32M	2.48M	4.4M	6.47M	3.9M	11.58M
Accounts Payable	1.21M	338K	418K	689K	329K	1.37M	1.81M	2.2M	967K	5.83M
Days Payables Outstanding	4.05K	3.52K	6.93K	22.86K	659.81	2.72K	3.39K	2.15K	943.73	5.93K
Short-Term Debt	0	3.45M	0	0	0	0	0	0	0	0
Deferred Revenue (Current)	0	-1000K	0	0	0	0	0	0	0	0
Other Current Liabilities	0	0	0	0	0	98K	1.51M	0	2M	1.6M
Current Ratio	10.90x	10.48x	13.19x	5.63x	7.54x	46.57x	20.07x	9.19x	14.41x	12.42x
Quick Ratio	10.90x	10.48x	13.19x	5.63x	6.88x	46.57x	20.07x	9.19x	14.41x	12.42x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	88K	84K	1.02M	1.84M	144K	4.11M	2.15M	2.13M	77.96M	47.69M
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	144K	0	400K	383K	0	640K
Deferred Tax Liabilities	0	0	0	0	0	4.11M	1.75M	0	1.75M	2.18M
Other Non-Current Liabilities	88K	0	0	0	0	0	0	1.75M	76.21M	44.87M
Total Liabilities	6.25M	2.9M	1.44M	2.53M	1.47M	6.59M	6.55M	8.61M	81.86M	59.27M
Total Debt+	0	3.45M	0	0	324K	144K	769K	746K	383K	954K
Net Debt	-24.02M	-19.78M	-17.23M	-12.97M	-8.47M	-114.05M	-84.06M	-55.66M	-4.23M	-19.59M
Debt / Equity	-	0.13x	-	-	0.03x	0.00x	0.00x	0.01x	0.05x	0.01x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-260.12x	-	-	-	-	-	-	-	-	-
Total Equity+	61.72M	26.86M	19.45M	14.49M	9.46M	190.6M	164M	84.18M	7.21M	118.14M
Equity Growth %	-0.4%	-0.56%	-0.28%	-0.25%	-0.35%	19.14%	-0.14%	-0.49%	-0.91%	15.39%
Book Value per Share	444.72	1263.13	74.85	28.97	14.44	131.32	11.07	5.89	0.29	2.43
Total Shareholders' Equity	61.72M	26.86M	19.45M	14.49M	9.46M	190.6M	164M	84.18M	7.21M	118.14M
Common Stock	23K	23K	7K	9K	13K	15K	14K	14K	24K	60K
Retained Earnings	-131.44M	-169.4M	-27.51M	-41.57M	-57.58M	-80.39M	-114.9M	-202.87M	-319.4M	-355.59M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-55K	-1K	0	0	0	0	0	0	0	26K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-41.24M	-36.52M	-14.94M	-11.89M	-13.86M	-15.21M	-28.91M	-28.42M	-39.53M	-47.27M
Operating CF Margin %	-	-	-	-	-	-	-	-	-	-
Operating CF Growth %	-0.95%	0.11%	0.59%	0.2%	-0.17%	-0.1%	-0.9%	0.02%	-0.39%	-0.2%
Net Income	-45.09M	-37.96M	-13.12M	-14.06M	-16.01M	-22.81M	-34.51M	-87.97M	-116.54M	-36.18M
Depreciation & Amortization	109K	171K	22K	11K	182K	183K	195K	373K	374K	359K
Stock-Based Compensation	2.9M	3M	579K	1.54M	1.31M	3.17M	0	8.15M	6.54M	13.12M
Deferred Taxes	72K	352K	0	0	0	-404K	-2.35M	0	0	431K
Other Non-Cash Items	-235K	-2K	49K	471K	1.87M	4.83M	7.9M	48.65M	75.01M	-33.71M
Working Capital Changes	1M	-2.08M	-2.48M	618K	-1.2M	-180K	-152K	2.37M	-4.92M	8.71M
Change in Receivables	0	0	0	0	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	443K	-778K	-1.96M	1.09M	-1.39M	-39K	2.14M	2.08M	-2.6M	7.75M
Cash from Investing+	-40.51M	35.68M	23.26M	0	0	11.04M	0	0	-45.29M	-70.31M
Capital Expenditures	-565K	-17K	0	0	0	0	0	0	0	0
CapEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-70K	2K	8K	0	0	0	0	0	0	0
Cash from Financing+	513K	37K	7.87M	7.56M	9.68M	109.58M	-449K	0	33.02M	133.52M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	-25K	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	513K	0	3.12M	71K	0	5.38M	0	0	0	215K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-41.8M	-36.54M	-14.94M	-11.89M	-13.86M	-15.21M	-28.91M	-28.42M	-39.53M	-47.27M
FCF Margin %	-	-	-	-	-	-	-	-	-	-
FCF Growth %	-0.98%	0.13%	0.59%	0.2%	-0.17%	-0.1%	-0.9%	0.02%	-0.39%	-0.2%
FCF per Share	-301.18	-1718.34	-57.49	-23.77	-21.14	-10.48	-1.95	-1.99	-1.61	-0.97
FCF Conversion (FCF/Net Income)	0.91x	0.96x	1.14x	0.85x	0.87x	0.67x	0.84x	0.32x	0.34x	1.31x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-54.58%	-85.7%	-56.64%	-82.87%	-133.66%	-22.8%	-19.46%	-70.89%	-255.03%	-57.73%
Return on Invested Capital (ROIC)	-188.87%	-127.69%	-211.61%	-564.05%	-844.96%	-25.69%	-35.34%	-55.02%	-204.77%	-104.28%
Debt / Equity	-	0.13x	-	-	0.03x	0.00x	0.00x	0.01x	0.05x	0.01x
Interest Coverage	-260.12x	-	-	-	-	-	-	-	-	-
FCF Conversion	0.91x	0.96x	1.14x	0.85x	0.87x	0.67x	0.84x	0.32x	0.34x	1.31x

Frequently Asked Questions

Growth & Financials

Eledon Pharmaceuticals, Inc. (ELDN) grew revenue by 0.0% over the past year. Growth has been modest.

Eledon Pharmaceuticals, Inc. (ELDN) reported a net loss of $79.8M for fiscal year 2024.

Dividend & Returns

Eledon Pharmaceuticals, Inc. (ELDN) has a return on equity (ROE) of -57.7%. Negative ROE indicates the company is unprofitable.

Eledon Pharmaceuticals, Inc. (ELDN) had negative free cash flow of $67.2M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Eledon Pharmaceuticals, Inc. (ELDN) 10-Year Financial Performance & Capital Metrics

ELDN • • Industrial / General

HealthcareBiotechnologyAutoimmune & Inflammatory DiseasesDermatology & Autoimmune

Revenue $0
EBITDA -$70M -64.7%
Net Income -$36M +69.0%
EPS (Diluted) -0.75 +54.3%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -57.73% +77.4%
ROIC -104.28% +49.1%
Debt/Equity 0.01 -84.8%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓High quality earnings: Operating CF exceeds net income
✓Trading at only 0.9x book value

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Weak momentum: RS Rating 12 (bottom 12%)
✗Shares diluted 97.2% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-3.08%

EPS CAGR

10Y-

5Y-

3Y-

TTM78.91%

ROCE

10Y Avg-56.91%

5Y Avg-34.27%

3Y Avg-45.97%

Latest-56.24%

Peer Comparison

Dermatology & Autoimmune

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
AUPHAurinia Pharmaceuticals Inc.	1.96B	14.87	378.37	33.97%	29.28%	21.28%	2.25%	0.21
ARGXargenx SE	50.33B	813.24	63.63	78.6%	23.34%	15.14%		0.01
INVAInnoviva, Inc.	1.48B	19.76	54.89	15.54%	32.78%	12.61%	12.75%	0.65
GLPGGalapagos N.V.	2.24B	34.03	30.38	14.99%	-151.94%	-15.16%		0.00
PTGXProtagonist Therapeutics, Inc.	5.3B	84.75	20.04	6.24%	21.94%	7.11%	3.45%	0.02
ALMSAlumis Inc. Common Stock	2.84B	24.17	-2.33		-11.08%	-63.71%		0.12
PHATPhathom Pharmaceuticals, Inc.	1.17B	14.98	-2.83	80.01%	-186.53%
ORKAOruka Therapeutics, Inc.	1.57B	32.50	-6.51			-22.44%		0.00

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-	-	-	-
Cost of Goods Sold+	109K	35K	22K	11K	182K	183K	195K	373K	374K	359K
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	-109K	-35K	-22K	-11K	-182K	-183K	-195K	-373K	-374K	-359K
Gross Margin %	-	-	-	-	-	-	-	-	-	-
Gross Profit Growth %	-1878.31%	0.68%	0.37%	0.5%	-15.55%	-0.01%	-0.07%	-0.91%	-0%	0.04%
Operating Expenses+	45.26M	38.12M	13.12M	14.06M	14M	13.1M	36.67M	39.41M	42.63M	70.22M
OpEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Selling, General & Admin	12.62M	13.1M	11.1M	7.24M	5.87M	6.97M	12.94M	12.33M	12.31M	18.25M
SG&A % of Revenue	-	-	-	-	-	-	-	-	-	-
Research & Development	32.64M	25.02M	2.02M	6.82M	8.13M	6.13M	23.73M	27.08M	30.31M	51.96M
R&D % of Revenue	-	-	-	-	-	-	-	-	-	-
Other Operating Expenses	0	0	5K	-5K	0	0	0	0	0	0
Operating Income+	-45.26M	-38.12M	-13.12M	-14.06M	-14.18M	-13.28M	-36.87M	-39.78M	-43M	-70.58M
Operating Margin %	-	-	-	-	-	-	-	-	-	-
Operating Income Growth %	-0.93%	0.16%	0.66%	-0.07%	-0.01%	0.06%	-1.78%	-0.08%	-0.08%	-0.64%
EBITDA+	-45.15M	-38.09M	-13.1M	-14.05M	-14M	-13.1M	-36.67M	-39.41M	-42.63M	-70.22M
EBITDA Margin %	-	-	-	-	-	-	-	-	-	-
EBITDA Growth %	-0.93%	0.16%	0.66%	-0.07%	0%	0.06%	-1.8%	-0.07%	-0.08%	-0.65%
D&A (Non-Cash Add-back)	109K	35K	22K	11K	182K	183K	195K	373K	374K	359K
EBIT	-45.09M	-6.93M	-13.12M	-14.06M	-16.01M	-23.21M	-36.86M	-87.97M	-116.54M	-35.75M
Net Interest Income+	0	0	0	0	0	0	0	0	0	0
Interest Income	0	0	0	0	0	0	0	0	0	0
Interest Expense	174K	0	0	0	0	0	0	0	0	0
Other Income/Expense	174K	-527K	5K	-5K	-1.83M	-9.93M	7K	-48.19M	-73.54M	34.82M
Pretax Income+	-45.09M	-37.96M	-13.12M	-14.06M	-16.01M	-23.21M	-36.86M	-87.97M	-116.54M	-35.75M
Pretax Margin %	-	-	-	-	-	-	-	-	-	-
Income Tax+	0	136K	0	-5K	0	-404K	-2.35M	0	0	431K
Effective Tax Rate %	1%	1%	1%	1%	1%	0.98%	0.94%	1%	1%	1.01%
Net Income+	-45.09M	-37.96M	-13.12M	-14.06M	-16.01M	-22.81M	-34.51M	-87.97M	-116.54M	-36.18M
Net Margin %	-	-	-	-	-	-	-	-	-	-
Net Income Growth %	-0.94%	0.16%	0.65%	-0.07%	-0.14%	-0.42%	-0.51%	-1.55%	-0.32%	0.69%
Net Income (Continuing)	-45.09M	-5.66M	-13.12M	-14.06M	-16.01M	-22.81M	-34.51M	-87.97M	-116.54M	-36.18M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-324.85	-1785.21	-50.47	-28.11	-27.27	-15.72	-2.33	-6.13	-1.64	-0.75
EPS Growth %	0.44%	-4.5%	0.97%	0.44%	0.03%	0.42%	0.85%	-1.63%	0.73%	0.54%
EPS (Basic)	-324.85	-1785.21	-50.47	-28.11	-27.27	-15.72	-2.33	-6.13	-0.00	-0.75
Diluted Shares Outstanding	138.79K	21.26K	259.87K	500.3K	655.52K	1.45M	14.82M	14.29M	24.62M	48.54M
Basic Shares Outstanding	138.79K	21.26K	259.87K	500.3K	655.52K	1.45M	14.82M	14.29M	24.62M	48.54M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	67.17M	29.54M	19M	14.28M	9.97M	115.63M	88.35M	59.52M	56.13M	143.73M
Cash & Short-Term Investments	63.96M	27.4M	17.23M	12.97M	8.79M	114.19M	84.83M	56.41M	51.1M	140.18M
Cash Only	24.02M	23.22M	17.23M	12.97M	8.79M	114.19M	84.83M	56.41M	4.61M	20.55M
Short-Term Investments	39.93M	4.17M	0	0	0	0	0	0	46.49M	119.63M
Accounts Receivable	0	0	0	594K	245K	110K	0	0	0	0
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	881K	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	1.77K	-	-	-	-	-
Other Current Assets	3.21M	47K	88K	36K	54K	38K	34K	28K	90K	729K
Total Non-Current Assets+	804K	218K	1.89M	2.75M	960K	81.56M	82.2M	33.27M	32.94M	33.67M
Property, Plant & Equipment	489K	98K	25K	14K	321K	138K	768K	739K	365K	926K
Fixed Asset Turnover	-	-	-	-	-	-	-	-	-	-
Goodwill	0	0	1.87M	1.87M	0	48.65M	48.65M	0	0	0
Intangible Assets	0	0	0	0	0	32.39M	32.39M	32.39M	32.39M	32.39M
Long-Term Investments	270K	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	45K	120K	0	869K	639K	383K	400K	150K	186K	363K
Total Assets+	67.97M	29.76M	20.89M	17.03M	10.93M	197.19M	170.55M	92.79M	89.07M	177.41M
Asset Turnover	-	-	-	-	-	-	-	-	-	-
Asset Growth %	-0.37%	-0.56%	-0.3%	-0.19%	-0.36%	17.04%	-0.14%	-0.46%	-0.04%	0.99%
Total Current Liabilities+	6.16M	2.82M	1.44M	2.53M	1.32M	2.48M	4.4M	6.47M	3.9M	11.58M
Accounts Payable	1.21M	338K	418K	689K	329K	1.37M	1.81M	2.2M	967K	5.83M
Days Payables Outstanding	4.05K	3.52K	6.93K	22.86K	659.81	2.72K	3.39K	2.15K	943.73	5.93K
Short-Term Debt	0	3.45M	0	0	0	0	0	0	0	0
Deferred Revenue (Current)	0	-1000K	0	0	0	0	0	0	0	0
Other Current Liabilities	0	0	0	0	0	98K	1.51M	0	2M	1.6M
Current Ratio	10.90x	10.48x	13.19x	5.63x	7.54x	46.57x	20.07x	9.19x	14.41x	12.42x
Quick Ratio	10.90x	10.48x	13.19x	5.63x	6.88x	46.57x	20.07x	9.19x	14.41x	12.42x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	88K	84K	1.02M	1.84M	144K	4.11M	2.15M	2.13M	77.96M	47.69M
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	144K	0	400K	383K	0	640K
Deferred Tax Liabilities	0	0	0	0	0	4.11M	1.75M	0	1.75M	2.18M
Other Non-Current Liabilities	88K	0	0	0	0	0	0	1.75M	76.21M	44.87M
Total Liabilities	6.25M	2.9M	1.44M	2.53M	1.47M	6.59M	6.55M	8.61M	81.86M	59.27M
Total Debt+	0	3.45M	0	0	324K	144K	769K	746K	383K	954K
Net Debt	-24.02M	-19.78M	-17.23M	-12.97M	-8.47M	-114.05M	-84.06M	-55.66M	-4.23M	-19.59M
Debt / Equity	-	0.13x	-	-	0.03x	0.00x	0.00x	0.01x	0.05x	0.01x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-260.12x	-	-	-	-	-	-	-	-	-
Total Equity+	61.72M	26.86M	19.45M	14.49M	9.46M	190.6M	164M	84.18M	7.21M	118.14M
Equity Growth %	-0.4%	-0.56%	-0.28%	-0.25%	-0.35%	19.14%	-0.14%	-0.49%	-0.91%	15.39%
Book Value per Share	444.72	1263.13	74.85	28.97	14.44	131.32	11.07	5.89	0.29	2.43
Total Shareholders' Equity	61.72M	26.86M	19.45M	14.49M	9.46M	190.6M	164M	84.18M	7.21M	118.14M
Common Stock	23K	23K	7K	9K	13K	15K	14K	14K	24K	60K
Retained Earnings	-131.44M	-169.4M	-27.51M	-41.57M	-57.58M	-80.39M	-114.9M	-202.87M	-319.4M	-355.59M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-55K	-1K	0	0	0	0	0	0	0	26K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-41.24M	-36.52M	-14.94M	-11.89M	-13.86M	-15.21M	-28.91M	-28.42M	-39.53M	-47.27M
Operating CF Margin %	-	-	-	-	-	-	-	-	-	-
Operating CF Growth %	-0.95%	0.11%	0.59%	0.2%	-0.17%	-0.1%	-0.9%	0.02%	-0.39%	-0.2%
Net Income	-45.09M	-37.96M	-13.12M	-14.06M	-16.01M	-22.81M	-34.51M	-87.97M	-116.54M	-36.18M
Depreciation & Amortization	109K	171K	22K	11K	182K	183K	195K	373K	374K	359K
Stock-Based Compensation	2.9M	3M	579K	1.54M	1.31M	3.17M	0	8.15M	6.54M	13.12M
Deferred Taxes	72K	352K	0	0	0	-404K	-2.35M	0	0	431K
Other Non-Cash Items	-235K	-2K	49K	471K	1.87M	4.83M	7.9M	48.65M	75.01M	-33.71M
Working Capital Changes	1M	-2.08M	-2.48M	618K	-1.2M	-180K	-152K	2.37M	-4.92M	8.71M
Change in Receivables	0	0	0	0	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	443K	-778K	-1.96M	1.09M	-1.39M	-39K	2.14M	2.08M	-2.6M	7.75M
Cash from Investing+	-40.51M	35.68M	23.26M	0	0	11.04M	0	0	-45.29M	-70.31M
Capital Expenditures	-565K	-17K	0	0	0	0	0	0	0	0
CapEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-70K	2K	8K	0	0	0	0	0	0	0
Cash from Financing+	513K	37K	7.87M	7.56M	9.68M	109.58M	-449K	0	33.02M	133.52M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	-25K	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	513K	0	3.12M	71K	0	5.38M	0	0	0	215K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-41.8M	-36.54M	-14.94M	-11.89M	-13.86M	-15.21M	-28.91M	-28.42M	-39.53M	-47.27M
FCF Margin %	-	-	-	-	-	-	-	-	-	-
FCF Growth %	-0.98%	0.13%	0.59%	0.2%	-0.17%	-0.1%	-0.9%	0.02%	-0.39%	-0.2%
FCF per Share	-301.18	-1718.34	-57.49	-23.77	-21.14	-10.48	-1.95	-1.99	-1.61	-0.97
FCF Conversion (FCF/Net Income)	0.91x	0.96x	1.14x	0.85x	0.87x	0.67x	0.84x	0.32x	0.34x	1.31x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-54.58%	-85.7%	-56.64%	-82.87%	-133.66%	-22.8%	-19.46%	-70.89%	-255.03%	-57.73%
Return on Invested Capital (ROIC)	-188.87%	-127.69%	-211.61%	-564.05%	-844.96%	-25.69%	-35.34%	-55.02%	-204.77%	-104.28%
Debt / Equity	-	0.13x	-	-	0.03x	0.00x	0.00x	0.01x	0.05x	0.01x
Interest Coverage	-260.12x	-	-	-	-	-	-	-	-	-
FCF Conversion	0.91x	0.96x	1.14x	0.85x	0.87x	0.67x	0.84x	0.32x	0.34x	1.31x

Frequently Asked Questions

Growth & Financials

Eledon Pharmaceuticals, Inc. (ELDN) grew revenue by 0.0% over the past year. Growth has been modest.

Eledon Pharmaceuticals, Inc. (ELDN) reported a net loss of $79.8M for fiscal year 2024.

Dividend & Returns

Eledon Pharmaceuticals, Inc. (ELDN) has a return on equity (ROE) of -57.7%. Negative ROE indicates the company is unprofitable.

Eledon Pharmaceuticals, Inc. (ELDN) had negative free cash flow of $67.2M in fiscal year 2024, likely due to heavy capital investments.